Universal Beteiligungs und Servicegesellschaft mbH Buys 70,320 Shares of Bristol Myers Squibb Company $BMY

Universal Beteiligungs und Servicegesellschaft mbH raised its position in Bristol Myers Squibb Company (NYSE:BMY) by 4.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,742,579 shares of the biopharmaceutical company’s stock after buying an additional 70,320 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Bristol Myers Squibb were worth $78,590,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Exchange Capital Management Inc. grew its stake in Bristol Myers Squibb by 0.4% in the 2nd quarter. Exchange Capital Management Inc. now owns 54,893 shares of the biopharmaceutical company’s stock valued at $2,541,000 after buying an additional 220 shares in the last quarter. Parsons Capital Management Inc. RI raised its position in Bristol Myers Squibb by 0.3% during the second quarter. Parsons Capital Management Inc. RI now owns 78,105 shares of the biopharmaceutical company’s stock valued at $3,615,000 after purchasing an additional 224 shares in the last quarter. Richwood Investment Advisors LLC boosted its stake in shares of Bristol Myers Squibb by 1.7% in the 2nd quarter. Richwood Investment Advisors LLC now owns 13,303 shares of the biopharmaceutical company’s stock valued at $616,000 after purchasing an additional 225 shares in the last quarter. Mccarter Private Wealth Services LLC boosted its stake in shares of Bristol Myers Squibb by 5.0% during the third quarter. Mccarter Private Wealth Services LLC now owns 4,931 shares of the biopharmaceutical company’s stock valued at $222,000 after purchasing an additional 235 shares during the period. Finally, Creative Financial Designs Inc. ADV raised its holdings in shares of Bristol Myers Squibb by 26.7% during the second quarter. Creative Financial Designs Inc. ADV now owns 1,123 shares of the biopharmaceutical company’s stock valued at $52,000 after acquiring an additional 237 shares in the last quarter. Institutional investors own 76.41% of the company’s stock.

More Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Partnership with Microsoft to pilot AI radiology for earlier lung‑cancer detection — strengthens BMY’s diagnostics and R&D capabilities, raises potential long‑term clinical and commercial benefits. Article Title
• Positive Sentiment: UBS upgraded BMY to Buy, noting an attractive risk/reward — an upward analyst stance that can support buying interest and higher valuation expectations. Article Title
• Positive Sentiment: Scotiabank and other outlets highlighted BMY as an appealing oncology/dividend pick and raised price targets — incremental analyst support that may buoy investor confidence. Article Title
• Neutral Sentiment: Industry coverage & stock lists (Zacks comparison with GSK; dividend‑stock ETFs and blue‑chip roundup pieces) keep BMY in investor screens but are broad‑market context rather than company‑specific catalysts. Article Title
• Negative Sentiment: Zacks issued mixed estimate moves: a tiny raise to Q4 2027 EPS (from $1.44 to $1.45) but cuts to Q1 2027 (1.36 → 1.33) and FY2027 (5.91 → 5.90). Those near‑term downgrades — even if small — can dampen sentiment and help explain intraday weakness as investors focus on near‑term earnings visibility.

Bristol Myers Squibb Price Performance

Bristol Myers Squibb stock opened at $54.20 on Wednesday. The company has a current ratio of 1.27, a quick ratio of 1.17 and a debt-to-equity ratio of 2.39. The company has a fifty day simple moving average of $52.18 and a 200-day simple moving average of $48.24. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $63.33. The stock has a market cap of $110.34 billion, a P/E ratio of 18.31, a price-to-earnings-growth ratio of 0.17 and a beta of 0.29.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $1.63 EPS for the quarter, topping the consensus estimate of $1.52 by $0.11. The business had revenue of $12.22 billion for the quarter, compared to analyst estimates of $11.75 billion. Bristol Myers Squibb had a net margin of 12.57% and a return on equity of 76.53%. The business’s revenue for the quarter was up 2.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.80 EPS. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. Equities analysts expect that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, February 2nd. Investors of record on Friday, January 2nd will be issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 4.6%. The ex-dividend date is Friday, January 2nd. This is a positive change from Bristol Myers Squibb’s previous quarterly dividend of $0.62. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 85.14%.

Analysts Set New Price Targets

Several brokerages recently weighed in on BMY. Wall Street Zen raised shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Wells Fargo & Company boosted their price target on shares of Bristol Myers Squibb from $53.00 to $55.00 and gave the stock an “equal weight” rating in a research report on Wednesday, December 10th. Morgan Stanley reiterated an “underweight” rating and set a $37.00 target price (up from $36.00) on shares of Bristol Myers Squibb in a research report on Friday, December 12th. Guggenheim reissued a “buy” rating on shares of Bristol Myers Squibb in a research report on Tuesday, December 23rd. Finally, Bank of America raised shares of Bristol Myers Squibb from a “neutral” rating to a “buy” rating and raised their price target for the stock from $52.00 to $61.00 in a report on Monday, December 15th. Seven research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $56.86.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.